Arcus Biosciences Inc. and partner Gilead Sciences Inc. are scrapping phase III work with anti-TIGIT antibody domvanalimab ...

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC ...

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for ...

Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...

Dec 12 () - Gilead Sciences ​and ‌Arcus Biosciences said ‌on Friday they would stop ⁠a ‌late-stage study testing ‍their ...

Alpelisib plus fulvestrant significantly improved PFS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, achieving a median PFS of 7.4 months versus 2.8 months with placebo. The ...

Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer.

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...